AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Selecta Biosciences Announces Pricing of Initial Public Offering

Selecta Biosciences Announces Pricing of Initial Public Offering

June 21, 2016

WATERTOWN, Mass., (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Selecta Biosciences.

Axcella to Present at the JMP Securities Life Sciences Conference

Axcella to Present at the JMP Securities Life Sciences Conference

June 15, 2016

CAMBRIDGE, Mass., – Axcella Health Inc., a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference in New York, N.Y. The presentation will take place June 22, 2016, at 3 p.m. EDT.

About Axcella Health

Axcella to Present at Jefferies 2016 Healthcare Conference

Axcella to Present at Jefferies 2016 Healthcare Conference

June 8, 2016

CAMBRIDGE, Mass., – Axcella Health Inc., a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference in New York, N.Y. The presentation will take place June 9, 2016, at 9 a.m. EDT.

About Axcella Health

Pronutria Biosciences Rebrands as Axcella Health

Pronutria Biosciences Rebrands as Axcella Health

June 7, 2016

Company Unveils Clinical Programs Across Three Disease Categories

CAMBRIDGE, Mass. – Pronutria Biosciences today announced that it has changed its corporate name to Axcella Health to better reflect its mission of harnessing amino acids for cell health through a systems pharmacology approach. The company uses oral protein biologics to precisely deliver disease-specific amino acid profiles that have systems-wide effects, which restore cell homeostasis and address underlying disease conditions.

TRANSMEDICS, INC. ANNOUNCES CLOSING OF $51.2 MILLION GROWTH FINANCING TO TRANSFORM ORGAN TRANSPLANT THERAPY

TRANSMEDICS, INC. ANNOUNCES CLOSING OF $51.2 MILLION GROWTH FINANCING TO TRANSFORM ORGAN TRANSPLANT THERAPY

May 26, 2016

TransMedics, Inc., a medical technology company dedicated to improving quality, assessing viability and increasing the utilization of donor organs for transplantation announces today the closing of $51.2 million growth equity financing.

The financing was co-led by global life science investors Fayerweather Fund, Pharmstandard International S.A. represented by InBio Ventures, Ervington Investments, and BioStar Ventures. In addition, existing investors Abrams Capital, Lung Biotechnology PBC, Flagship Ventures and KPCB participated in this financing.

Joule appoints William J. Brady Jr. to Board of Directors

Joule appoints William J. Brady Jr. to Board of Directors

May 24, 2016

BEDFORD, Mass.--(BUSINESS WIRE)--Joule, a leading low carbon fuels company, today announced the appointment of William J. Brady Jr. to the company’s board of directors. Mr. Brady is an industry leader who brings extensive experience from his 25-year career at top-tier renewable fuels and chemicals companies.

Codiak BioSciences Names Jan Lötvall, M.D., Ph.D., Chief Scientist

Codiak BioSciences Names Jan Lötvall, M.D., Ph.D., Chief Scientist

May 17, 2016

WOBURN, Mass., May 17, 2016 /PRNewswire/ -- Codiak BioSciences Inc., a leading company in the field of exosome biology, today announced the appointment of Jan Lötvall, M.D., Ph.D., as Chief Scientist. As a member of the executive leadership team, Dr. Lötvall will report to Douglas E. Williams, Ph.D., President and CEO, and will continue his pioneering research on the potential of exosomes for therapeutic uses. He will begin his new position this summer, working on a consulting basis during his relocation from Gothenburg, Sweden.

Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease

Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease

May 12, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has entered into a multi-year collaboration with leading microbiome clinical-scientists from the University of Pennsylvania (Penn) to support the development of novel treatment approaches for certain rare genetic metabolic diseases including urea cycle disorders, and inflammatory bowel disease (IBD).